CONFLICT OF INTEREST
The authors have no conflict of interest. The study wasdesigned under the responsibility of EverNov Medicines. The study was funded by EverNov Medicines. EVER4010001 was provided by EverNov Medicines and pembrolizumab was provided by Merck Sharp & Dohme Corp. EverNov Medicines collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.